tradingkey.logo
tradingkey.logo
Search

Inhibrx Biosciences Inc

INBX
Add to Watchlist
97.580USD
+2.640+2.78%
Close 07/02, 13:00ETQuotes delayed by 15 min
1.43BMarket Cap
LossP/E TTM

TradingKey Stock Score of Inhibrx Biosciences Inc

Currency: USD Updated: 2026-07-02

Key Insights

Inhibrx Biosciences Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 62 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 277.50.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Inhibrx Biosciences Inc's Score

Industry at a Glance

Industry Ranking
62 / 387
Overall Ranking
152 / 4565
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Inhibrx Biosciences Inc Highlights

StrengthsRisks
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.30M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -11.63, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 12.34M shares, increasing 7.43% quarter-over-quarter.
Held by Andreas Halvorsen
Star Investor Andreas Halvorsen holds 954.08K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.71.

Analyst Rating

Based on 3 analysts
Buy
Current Rating
277.500
Target Price
+192.29%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Inhibrx Biosciences Inc?

The TradingKey Stock Score provides a comprehensive assessment of Inhibrx Biosciences Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Inhibrx Biosciences Inc’s performance and outlook.

How do we generate the financial health score of Inhibrx Biosciences Inc?

To generate the financial health score of Inhibrx Biosciences Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Inhibrx Biosciences Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Inhibrx Biosciences Inc.

How do we generate the company valuation score of Inhibrx Biosciences Inc?

To generate the company valuation score of Inhibrx Biosciences Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Inhibrx Biosciences Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Inhibrx Biosciences Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Inhibrx Biosciences Inc.

How do we generate the earnings forecast score of Inhibrx Biosciences Inc?

To calculate the earnings forecast score of Inhibrx Biosciences Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Inhibrx Biosciences Inc’s future.

How do we generate the price momentum score of Inhibrx Biosciences Inc?

When generating the price momentum score for Inhibrx Biosciences Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Inhibrx Biosciences Inc’s prices. A higher score indicates a more stable short-term price trend for Inhibrx Biosciences Inc.

How do we generate the institutional confidence score of Inhibrx Biosciences Inc?

To generate the institutional confidence score of Inhibrx Biosciences Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Inhibrx Biosciences Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Inhibrx Biosciences Inc.

How do we generate the risk management score of Inhibrx Biosciences Inc?

To assess the risk management score of Inhibrx Biosciences Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Inhibrx Biosciences Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Inhibrx Biosciences Inc.